Showing posts with label LSD. Show all posts
Showing posts with label LSD. Show all posts

Microdosing with LSD

SUBHEAD: It's a growing phenomena in Silicon Valley. But does it actually work?

By Dominique Mosbergen on 3 September 2018 for Huffington Post -
(https://www.huffingtonpost.com/entry/microdosing-lsd-placebo-study_us_5b8d1e48e4b0511db3daaaff)

http://www.islandbreath.org/2018Year/09/180905hofmannbig.jpg
Image above: Painting titled "St. Albert" by the artist Alex Gray. Dr. Albert Hofmann is the Swiss chemist who discovered LSD, thus catalyzing a consciousness revolution. Surrounding Hofmann in the painting are luminaries who have written about the powerful positive influence of psychedelics. The painting was completed as part of Dr. Albert Hofmann's 100th birthday celebration held in Basel, Switzerland on January 11th, 2006. From (https://shop.cosm.org/collections/artwork) Click to enlarge.

[IB Publisher's note: About friggin' time! It's been 75 years since LSD was discovered. The drug has had a government sponsored propaganda reputation almost as incorrect as that for marijuana. It has taken half a century of my life to get the issue of the usefulness of cannabis/hemp settled. Remember NORML?] 

A powerful distortion and alteration of perception, mood and cognitive function: The effects of taking larger amounts of psychedelic drugs like LSD and magic mushrooms are fairly well documented and understood.

But when it comes to the growing trend of microdosing or taking very small quantities of these drugs on a regular basis, the science is hazy.

Anecdotally, people who microdose with psychedelics have claimed the drugs deliver a range of benefits such as heightened focus, productivity and creativity, as well as psychological and emotional well-being.

The effects are apparently so positive that microdosing has been described as the “life hack du jour” in Silicon Valley, where the practice first gained widespread popularity.

Yet, despite the burgeoning interest in the technique, research into microdosing and its effects remain scarce ― though scientific interest does appear to be growing.

“If you look around in the scientific literature, you realize there are virtually no studies on [this topic],” neuroscience researcher Balazs Szigeti told Wired magazine in a recent interview.

On Monday, Szigeti and a team of colleagues are working to change this fact with the launch of one of the first ever placebo-controlled trials of microdosing.

The study, which is supported by Imperial College London and the Beckley Foundation, a U.K.-based think tank that funds psychedelic research, aims to find out whether microdosing of LSD actually delivers the positive benefits that users claim — or whether it’s merely a placebo effect.

“As a scientist working in the field, it just feels not very satisfying that something explosively used by a lot of people is basically so non-evidence-based,” David Erritzoe, the study’s principal investigator, told Wired.

For cost and feasibility reasons, the study will not be conducted in a lab but will instead involve adult subjects who have been recruited online and who already microdose with LSD or intend to.

The researchers will not provide the drugs but will facilitate a “self-blinding” procedure that will involve sending the participants eight envelopes with QR codes on them.

The subjects will have to fill these envelopes themselves with either empty pills (the placebo) or capsules with LSD microdoses in them.

The participants will then have to mix the eight envelopes up and pick only four of them, each corresponding to one week in the four-week trial.

Once the trial begins, the subjects will take one pill every morning from that week’s envelope ― though they won’t know whether they’re consuming LSD or a dummy pill.

According to the study’s website, participants will be required throughout the study to “complete a set of online questionnaires and to play a selection of online cognitive games.

The questionnaires focus on examining the psychological state of participants, while the online games have been designed to measure cognitive performance.”

As Wired noted, the study has some clear advantages but also inherent problems. “An advantage of the at-home study is that it can accommodate a large number of potential participants, which means more data,” the magazine said.

“A disadvantage, however, is that researchers will have to rely on people following their instructions correctly, reporting back accurately and not breaking the self-blinding mechanism.”

Still, the researchers say they are hopeful that this innovative trial will offer more insight into microdosing’s effects.

“One can’t and doesn’t want to encourage people to microdose, but it is interesting to try to gather data in a slightly more scientific way from people who are doing it,” Amanda Feilding, director of the Beckley Foundation, told The Guardian of the new research.

See also:
Ea O Ka Aina: Be Your Own Medicine 1/31/16
Ea O Ka Aina: Deadhead Security Alert
4/7/15
Ea O Ka Aina: 10 Things about Steve Jobs 8/24/11
Ea O Ka Aina: Psychedelics are "Born Illegal"
1/10/10
Ea O Ka Aina: Fear and Loathing in America 1/20/06
.

Clinical LSD Study Completed

SUBHEAD: The final subject in the first clinical LSD study since 1972 just completed his last treatment.  

By David Jay Brown on 27 May 2011 for Santa Cruz Patch - 
(http://santacruz.patch.com/articles/landmark-clinical-lsd-study-nears-completion)

 
Image above: Portrait of Albert Hoffman with LSD nmolecule by Alex Gray. From (http://www.gashaus.com/component/content/article/769.html).
 
The first clinical LSD study on the planet in more than 35 years is almost complete. The Santa Cruz Multidisciplinary Association for Psychedelic Studies (MAPS) is sponsoring this research, which began in 2008, when Swiss psychiatrist Peter Gasser, M.D., became the first medical researcher in the world to obtain government approval to do therapeutic research with LSD since 1972.

Before 1972, nearly 700 studies with LSD and other psychedelic drugs were conducted. This research suggested that LSD has remarkable medical potential. LSD-assisted psychotherapy was shown to reduce the anxiety of terminal cancer patients, the drinking of alcoholics and the symptoms of many difficult-to-treat psychiatric illnesses.

For example, early LSD studies with advanced-stage cancer patients showed that LSD-assisted psychotherapy could alleviate symptoms of anxiety, tension, depression, sleep disturbances, psychological withdrawal and even severe physical pain. Other early investigators found that LSD may have some valuable potential as a means to facilitate creativity, problem-solving abilities and spiritual awareness.

Between 1972 and 1990 there were no government-approved human studies with any psychedelic drugs anywhere in the world. Their disappearance was no mystery. The worldwide ban on psychedelic drug research was the result of a political backlash that followed the promotion of these drugs by the counterculture of the 1960s. This reaction not only made these substances illegal for personal use, it also made it extremely difficult for medical researchers to obtain government approval to study them.

The situation began to change in 1990 when, according to MAPS president Rick Doblin, “open-minded regulators at the FDA decided to put science before politics when it came to psychedelic and medical marijuana research.” There are now more than a half-dozen clinical studies occurring worldwide that are examining the medical potential of psychedelic drugs.

Gasser’s almost-completed, MAPS-sponsored LSD study is being conducted in Switzerland, where LSD was discovered in 1943 by Albert Hofmann. The study examines how LSD-assisted psychotherapy affects the anxiety associated with suffering from an advanced, life-threatening illness. There are 12 subjects in the study with advanced-stage cancer and other serious illnesses.

According to Gasser, so far the results look promising. Early researchers found that LSD-assisted psychotherapy has the incredible ability to help many people overcome their fear of death, and this is probably a major contributing factor in why the drug can be so profoundly helpful when people are facing a life-threatening illness.

On May 26, the final subject in Gasser’s study completed his last experimental therapy session. The clinical team at MAPS is now conducting a preliminary data analysis, finalizing the study’s database for the FDA and assisting Gasser in preparing a manuscript for publication.

MAPS is also sponsoring other medical research into the psychotherapeutic potential of psychedelic drugs, and more studies are on the way. The medical and therapeutic value of LSD and other psychedelic drugs appears to be quite substantial—although, personally, I’m really looking forward to the day when this research can go beyond its initial potential as a psychotherapeutic tool, as well as a spiritual aid, and delve into the mysteries of creativity, psychic phenomena and the possible reality of parallel universes and non-human entity contact.

Meanwhile, it seems like these mysterious substances hold enormous potential for treating numerous psychiatric disorders. Evidence suggests that they have the ability to help us treat post-traumatic stress disorder, depression, obsessive compulsive disorder, end-of-life anxiety, cluster headaches and other difficult-to-treat mental disorders—including, I suspect, the general neurosis that comes from simply being a human being.

To read the interview that I did with LSD researcher Peter Gasser, see:
maps.org/news-letters/v20n1/v20n1-42to43.pdf

To find out more about MAPS and medical research into psychedelic drugs, see:
maps.org

If you enjoy my column, and want to learn more about psychedelic and cannabis culture, “like” my Facebook page:
facebook.com/pages/David-Jay-Brown/115740098445882?ref=ts

and follow me on Twitter:
twitter.com/#!/DavidJayBrown

.